XOANACYL

This brand name is authorized in Austria, Estonia, Italy, Lithuania.

Active ingredients

The drug XOANACYL contains one active pharmaceutical ingredient (API):

1	Iron(III) citrate UNII 63G354M39Z - FERRIC CITRATE ANHYDROUS
	Ferric citrate coordination complex is specifically designed to have a high surface area and a defined molar ratio of ferric iron to citrate. The high surface area of ferric citrate coordination complex impacts ferric iron solubility at physiological pH and allows part of ferric iron to be absorbed and supply iron to the metabolic pathway. Ferric citrate coordination complex has a dual mechanism of action, one that is associated with providing a source of ferric iron and one associated with decreasing the absorption of phosphorous.
	Read more about Ferric citrate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XOANACYL Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AE08		V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
Discover more medicines within V03AE08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3119105
IT	Agenzia del Farmaco	052308018
LT	Valstybinė vaistų kontrolės tarnyba	1103832